Latest Breaking News On - Brad margus - Page 1 : comparemela.com

Adrestia Therapeutics Partners with Leading Patient Advocacy Groups to Form Ataxia Telangiectasia Research Consortium

Consortium to advance R&D towards disease modifying drugs for fatal neurodegenerative pediatric diseases driven by inability to repair DNA damage A-T Children's Project, AT Society and Action

Arvinas Announces Changes to its Board of Directors

NEW HAVEN, Conn., Dec. 16, 2022 (GLOBE NEWSWIRE) Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs.

Arvinas Inc. (ARVN) Announces Changes to its Board of Directors

Positive results for Cerevance's Parkinson's drug

In phase 2 trials, the drug reduced ‘OFF time’ which refers to periods of the day when Parkinson’s symptoms recur despite medication - News - PharmaTimes

Cerevance Appoints Carrie Ann Cook As Chief Business Officer

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Cerevance Appoints Carrie Ann Cook As Chief Business Officer CerevanceFebruary 1, 2021 GMT BOSTON, Feb. 01, 2021 (GLOBE NEWSWIRE) Cerevance, a private drug discovery and development company focused on brain diseases, today announced the appointment of Carrie Ann Cook, a global business development executive with more than 20 years of experience in the pharmaceutical industry, as chief business officer effective February 1, 2021.   Ms. Cook most recently served as senior vice president/global head of business development at CANbridge Pharmaceuticals Inc., in Cambridge, MA. Prior to this position, she served as senior director, center for external innovation, rare disease, at Takeda Pharmaceuticals, where she led and executed research and development transactions. Ms. Cook previously served as head of global business development & licensing, MS, medical devices and global health at E